Compare AGX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | RDY |
|---|---|---|
| Founded | 1961 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.9B |
| IPO Year | 1995 | 2001 |
| Metric | AGX | RDY |
|---|---|---|
| Price | $589.09 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $409.50 | $16.90 |
| AVG Volume (30 Days) | 273.0K | ★ 2.9M |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | 0.32% | ★ 0.52% |
| EPS Growth | ★ 58.37 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $944,606,000.00 | N/A |
| Revenue This Year | $33.81 | $7.72 |
| Revenue Next Year | $20.97 | $3.50 |
| P/E Ratio | $178.46 | ★ $18.67 |
| Revenue Growth | ★ 8.06 | N/A |
| 52 Week Low | $197.00 | $11.36 |
| 52 Week High | $805.75 | $15.67 |
| Indicator | AGX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.55 |
| Support Level | N/A | $11.47 |
| Resistance Level | N/A | $13.95 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 58.00 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.